Award details

Evaluation of optimised heparins as novel therapeutics for Alzheimers Disease

ReferenceBB/D525713/1
Principal Investigator / Supervisor Professor Jeremy Turnbull
Co-Investigators /
Co-Supervisors
Institution University of Liverpool
DepartmentSch of Biological Sciences
Funding typeResearch
Value (£) 59,839
StatusCompleted
TypeResearch Grant
Start date 08/05/2006
End date 07/08/2007
Duration15 months

Abstract

The key step in the generation of toxic Abeta peptides that cause Alzheimer's disease (AD) is the action of an enzyme known as BACE1. We have recently discovered that a naturally occurring complex sugar called heparan sulphate (HS) is a regulator of BACE1 activity. The anti-coagulant drug heparin is a member of the HS family of molecules and we have generated a semi-synthetic modified heparin as a lead compound which is a powerful BACE1 inhibitor, has very low anticoagulant activity, and is not toxic in mice. Optimised heparins thus have potential as a new class of anti-AD drugs. In this proposal we will test a novel modified heparin in a validated mouse model of AD, and make initial assessments of the bioavailability of the compound and its ability to cross the blood/brain barrier. An assessment of the potential market for a novel heparin-based Alzheimer's drug will also be made. The overall goal of this project will be to establish proof-of-concept in an animal model of the use of an optimised heparin as a novel treatment for Alzheimer's Disease. This will enhance the opportunities for commercial exploitation through either a licening deal or development of a spin out company.

Summary

unavailable
Committee Closed Committee - Biochemistry & Cell Biology (BCB)
Research TopicsX – not assigned to a current Research Topic
Research PriorityX – Research Priority information not available
Research Initiative Follow-On Fund (FOF) [2004-2015]
Funding SchemeX – not Funded via a specific Funding Scheme
terms and conditions of use (opens in new window)
export PDF file